Knockdown assays targeting ANLN expression revealed dramatically reduced aggressive phenotypes (cell growth, migration, and invasion) of cancer cells, including pancreatic, breast, and lung cancers [30,31,32]. This evidence concerns the gene ANLN and lung cancer.